BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22983505)

  • 21. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
    Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
    Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. K-ras gene mutation analysis to diagnosis pancreatic adenocarcinoma from endoscopic ultrasound-guided tissue acquisition; a systematic review and meta-analysis.
    Tamura T; Ashida R; Wan K; Shimokawa T; Kitano M
    Pancreatology; 2024 Feb; 24(1):78-87. PubMed ID: 38042675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.
    Maluf-Filho F; Kumar A; Gerhardt R; Kubrusly M; Sakai P; Hondo F; Matuguma SE; Artifon E; Monteiro da Cunha JE; César Machado MC; Ishioka S; Forero E
    J Clin Gastroenterol; 2007; 41(10):906-10. PubMed ID: 18090159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
    Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
    Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
    Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
    J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.
    Däbritz J; Preston R; Hänfler J; Oettle H
    Pancreas; 2012 Mar; 41(2):323-5. PubMed ID: 22044911
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.
    Tao LY; Zhang LF; Xiu DR; Yuan CH; Ma ZL; Jiang B
    World J Surg Oncol; 2016 May; 14():146. PubMed ID: 27183870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis.
    Ren J; Li G; Ge J; Li X; Zhao Y
    Dis Colon Rectum; 2012 Aug; 55(8):913-23. PubMed ID: 22810479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients.
    Ulivi P; Romagnoli M; Chiadini E; Casoni GL; Capelli L; Gurioli C; Zoli W; Saragoni L; Dubini A; Tesei A; Amadori D; Poletti V
    Int J Oncol; 2012 Jul; 41(1):147-52. PubMed ID: 22504767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
    Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
    [No Abstract]   [Full Text] [Related]  

  • 33. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
    Hijioka S; Hosoda W; Mizuno N; Hara K; Imaoka H; Bhatia V; Mekky MA; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutumi H; Fujiyoshi T; Sato T; Hieda N; Yoshida T; Okuno N; Shimizu Y; Yatabe Y; Niwa Y; Yamao K
    J Gastroenterol; 2015 May; 50(5):564-72. PubMed ID: 25142799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of DNA Profiling From Main Pancreatic Duct Fluid by Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography to Screen for Malignant Potential.
    Simpson RE; Flick KF; Gromski MA; Al-Haddad MA; Easler JJ; Sherman S; Fogel EL; Schmidt CM; DeWitt JM
    Pancreas; 2020; 49(5):714-722. PubMed ID: 32433411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. K-ras gene mutation in the diagnosis of ultrasound guided fine-needle biopsy of pancreatic masses.
    Zheng M; Liu LX; Zhu AL; Qi SY; Jiang HC; Xiao ZY
    World J Gastroenterol; 2003 Jan; 9(1):188-91. PubMed ID: 12508380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.
    Pérez-Ruiz E; Rueda A; Pereda T; Alcaide J; Bautista D; Rivas-Ruiz F; Villatoro R; Pérez D; Redondo M
    Tumour Biol; 2012 Dec; 33(6):1829-35. PubMed ID: 22791568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
    Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
    Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor.
    Tada M; Komatsu Y; Kawabe T; Sasahira N; Isayama H; Toda N; Shiratori Y; Omata M
    Am J Gastroenterol; 2002 Sep; 97(9):2263-70. PubMed ID: 12358243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer.
    Salek C; Minarikova P; Benesova L; Nosek V; Strnad R; Zavoral M; Minarik M
    Anticancer Res; 2009 May; 29(5):1803-10. PubMed ID: 19443408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.